3D-QSAR and molecular docking for the discovery of ketolide derivatives

Bibliography

• Chopra I. Protein synthesis as a target for antibacterial drugs: current status and future opportunities. Expert Opin Investig Drugs 1998;7:1237-44
   PubMedGoogle Scholar
• Bryskier A. New research in macrolides and ketolides since 1997. Expert Opin Investig Drugs 1999;8:1171-94
   PubMedGoogle Scholar
• Wu Y-J, Su W-G. Recent developments on ketolides and macrolides. Curr Med Chem 2001;8:1727-58
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Dueck M, Hoban DJ, Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001;61:443-98
   PubMed Web of Science ®Google Scholar
• Nightingale CH, Mattoes HM. Macrolide, azalide, and ketolide pharmacodynamics. Infect Dis Ther 2002;28:205-20
   Google Scholar
• Asaka T, Manaka A, Sugiyama H. Recent developments in macrolide antimicrobial research. Curr Top Med Chem 2003;3:961-89
   PubMed Web of Science ®Google Scholar
• Agouridas C, Benedetti Y, Bonnefoy A, Ketolides: a new class of macrolide antibacterials - structural characteristics and biological properties of RU 004. Infect Dis Ther 1997;21:279-85
   Google Scholar
• Bryskier A, Agouridas C, Chantot J-F. Ketolides: new semisynthetic 14-membered-ring macrolides. Infect Dis Ther 1997;21:39-50
   Google Scholar
• Anderson RC, Harris PN, Chen K. Further toxicological studies with ilotycin® (Erythromycin, Lilly). J Am Pharm Assoc 1955;44(4):199-204
   Google Scholar
• Kurath P, Jones PH, Egan RS, Acid degradation of erythromycin A and erythromycin B. Cell Mol Life Sci 1971;27(4):362
   Google Scholar
• Ludden T. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985;10(1):63
   PubMed Web of Science ®Google Scholar
• Barre J, Mallat A, Rosenbaum J, Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 1987;23(6):753
   PubMed Web of Science ®Google Scholar
• Weber F Jr, Richards R, McCallum R. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993;88(4):485
   PubMed Web of Science ®Google Scholar
• Morimoto S, Takahashi Y, Watanabe Y, Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J Antibiot (Tokyo) 1984;37(2):187
   PubMed Web of Science ®Google Scholar
• Peters D, Friedel H, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44(5):750
   PubMed Web of Science ®Google Scholar
• Piscitelli S, Danziger L, Rodvold K. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992;11(2):137
   PubMedGoogle Scholar
• Dunn C, Barradell L. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996;51(3):483
   PubMed Web of Science ®Google Scholar
• Ballow C, Amsden G. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992;26(10):1253-61
   PubMed Web of Science ®Google Scholar
• Retsema J, Girard A, Schelkly W, Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987;31(12):1939-47
   PubMed Web of Science ®Google Scholar
• Baldwin D, Wise R, Andrews J, Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990;3(8):886-90
   PubMed Web of Science ®Google Scholar
• Tateda K, Comte R, Pechere JC, Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45(6):1930-3
   PubMed Web of Science ®Google Scholar
• Doern GV, Heilmann KP, Huynh HK, Antimicrobial resistance among clinical isolates of streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother 2001;45(6):1721-9
   PubMed Web of Science ®Google Scholar
• Richter S, Heilmann K, Coffman S, The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994–2000. Clin Infect Dis 2002;34(3):330
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Dueck M, Hoban DJ, Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001;61(4):443-98
   PubMed Web of Science ®Google Scholar
• Hoban DJ, Zhanel GG. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Expert Rev Anti Infect Ther 2006;4(6):973-80
   PubMedGoogle Scholar
• Felmingham D, Cantón R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001–2004. J Infect 2007;55(2):111-18
   PubMed Web of Science ®Google Scholar
• Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39(3):577
   PubMed Web of Science ®Google Scholar
• Seppälä H, Skurnik M, Soini H, A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pyogenes. Antimicrob Agents Chemother 1998;42(2):257-62
   PubMed Web of Science ®Google Scholar
• Farrell D, Morrissey I, Bakker S, Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002;50(Suppl 2):39-47
   PubMedGoogle Scholar
• Bryskier A, Agouridas C, Chantot JF. Ketolide: novel antibacterial agent designed to overcome erythromycin A resistance. Infect Dis Ther 2000;23:79-102
   Google Scholar
• Chu DTW. Chapter 13. Progress in macrolide and ketolide antibacterials. Annu Rep Med Chem 2000;35:145-55
   Web of Science ®Google Scholar
• Sorbera LA, Rabasseda X, Castaner J. ABT-773. Drugs Future 2000;25:445-53
   Web of Science ®Google Scholar
• Balfour JAB, Figgitt DP. Telithromycin. Drugs 2001;61:815-29
   PubMed Web of Science ®Google Scholar
• Dougherty TJ, Barrett JF. ABT-773. A new ketolide antibiotic. Expert Opin Investig Drugs 2001;10:343-51
   PubMed Web of Science ®Google Scholar
• Johnson AP. Telithromycin. aventis pharma. Curr Opin Investig Drugs 2001;2:1691-701
   PubMedGoogle Scholar
• Lawrence LE. ABT-773 (Abbott Laboratories). Curr Opin Investig Drugs 2001;2:766-72
   PubMedGoogle Scholar
• Yassin HM, Dever LL. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections. Expert Opin Investig Drugs 2001;10:353-67
   PubMed Web of Science ®Google Scholar
• Kaneko T, Romero K, Li B, Novel tethers in ketolide antibiotics. Bioorg Med Chem Lett 2007;17:5049-53
   PubMed Web of Science ®Google Scholar
• Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
   PubMed Web of Science ®Google Scholar
• Marrie TJ. Novel uses of macrolides, azalides, streptogramins, and ketolides in treating emerging pathogens. Infect Dis Ther 2000;23:277-82
   Google Scholar
• Mayer KH, Clumeck N. Use of the newer macrolide, azalide, streptogramin, and ketolide antibiotics for mycobacterial and other HIV-related diseases. Infect Dis Ther 2000;23:393-403
   Google Scholar
• Mole L. Drug interactions with macrolides and related structures. Infect Dis Ther 2000;23:25-34
   Google Scholar
• Moreillon P. Resistance to macrolides-lincosamides-streptogramins and ketolides in staphylococci and streptococci, and new therapeutic strategies. Infect Dis Ther 2000;23:197-207
   Google Scholar
• Doucet-Populaire F, Buriankova K, Weiser J, Natural and acquired macrolide resistance in mycobacteria. Curr Drug Targets Infect Disord 2002;2:355-70
   PubMedGoogle Scholar
• Brown SD. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia. Drug Saf 2008;31(7):561-75
   PubMed Web of Science ®Google Scholar
• Jabes D. The antibiotic R&D pipeline: an update. Curr Opin Microbiol 2011;14:564-9
   PubMed Web of Science ®Google Scholar
• Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann NY Acad Sci 2011;1241(1):122-52
   PubMedGoogle Scholar
• Bush K, Pucci MJ. New antimicrobial agents on the horizon. Biochem Pharmacol 2011;82:1528-39
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Hisanaga T, Nichol K, Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Expert Opin Emerg Drugs 2003;8:297-321
   PubMedGoogle Scholar
• Bermudez LE, Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. Curr Pharm Des 2004;10:3221-8
   PubMed Web of Science ®Google Scholar
• Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091-124
   PubMed Web of Science ®Google Scholar
• Wellington K, Noble S. Telithromycin. Drugs 2004;64:1683-94
   PubMed Web of Science ®Google Scholar
• Alekshun MN. New advances in antibiotic development and discovery. Expert Opin Investig Drugs 2005;14(2):117-34
   PubMed Web of Science ®Google Scholar
• Jain S, Bishai W, Nightingale CH. Macrolide, azalide, and ketolides. Infect Dis Ther 2007;44:217-30
   Google Scholar
• Davis S. Macrolides and ketolides: more than just antimicrobials. SA Pharm J 2011;78(6):24-7
   Google Scholar
• Fernandes P, Pereira D, Jamieson B, Solithromycin: macrolide antibiotic. Drugs Future 2011;36:751-8
   Web of Science ®Google Scholar
• McCoy LS, Xie Y, Tor Y. Antibiotics that target protein synthesis. Wiley Interdiscip Rev RNA 2011;2(2):209-32
   PubMed Web of Science ®Google Scholar
• Pal S. A journey across the sequential development of macrolides and ketolides related to erythromycin. Tetrahedron 2006;62(14):3171-200
   Web of Science ®Google Scholar
• Mutak S. Azalides from azithromycin to new azalide derivatives. J Antibiot (Tokyo) 2007;60(2):85-122
   PubMed Web of Science ®Google Scholar
• Fajdetic A, Cipcic PH, Lazarevski G, 4′′-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens. Bioorg Med Chem 2010;18:6559-68
   PubMed Web of Science ®Google Scholar
• Zhu B, Marinelli BA, Abbanat D, Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives. Bioorg Med Chem Lett 2007;17(14):3900-4
   PubMed Web of Science ®Google Scholar
• Grant EB, Guiadeen D, Abbanat D, Synthesis and antibacterial activity of 6-O-heteroaryl-carbamoyl-11,12-lacto-ketolides. Bioorg Med Chem Lett 2006;16:1929-33
   PubMedGoogle Scholar
• Tennakoon MA, Henninger TC, Abbanat D, Synthesis and antibacterial activity of C6-carbazate ketolides. Bioorg Med Chem Lett 2006;16:6231-5
   PubMed Web of Science ®Google Scholar
• Henninger TC, Xu X, Abbanat D, Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics. Bioorg Med Chem Lett 2004;14:4495-9
   PubMed Web of Science ®Google Scholar
• Xu X, Henninger T, Abbanat D, Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes. Bioorg Med Chem Lett 2005;15:883-7
   PubMed Web of Science ®Google Scholar
• Beebe X, Yang F, Bui MH, Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides. Bioorg Med Chem Lett 2004;14:2417-21
   PubMed Web of Science ®Google Scholar
• Yong H, Gui GY, Clark RF, Design, synthesis and structure-activity relationships of 6-O-arylpropargyl diazalides with potent activity against multidrug-resistant Streptococcus pneumoniae. Bioorg Med Chem Lett 2005;15:2653-8
   PubMed Web of Science ®Google Scholar
• Nomura T, Iwaki T, Yasukata T, A new type of ketolides bearing an N-aryl-alkyl acetamide moiety at the C-9 imino ether synthesis and structure-activity relationships. Bioorg Med Chem 2005;13:6615-28
   PubMed Web of Science ®Google Scholar
• Nomura T, Iwaki T, Narukawa Y, A new type of ketolide bearing an N-aryl-alkyl acetamide moiety at the C-9 iminoether: synthesis and structure-activity relationships. Bioorg Med Chem 2006;14:3697-711
   PubMed Web of Science ®Google Scholar
• Burger MT, Hiebert C, Seid M, Synthesis and antibacterial activity of novel C12 ethyl ketolides. Bioorg Med Chem 2006;14:5592-604
   PubMed Web of Science ®Google Scholar
• Burger MT, Lin X, Chu DT, Synthesis and antibacterial activity of novel C12 vinyl ketolides. J Med Chem 2006;49:1730-43
   PubMed Web of Science ®Google Scholar
• Lin X, Rico AC, Chu DT, Synthesis and antibacterial activity of C12 des-methyl ketolides. Bioorg Med Chem Lett 2006;16:4692-6
   PubMed Web of Science ®Google Scholar
• Magee TV, Ripp SL, Li B, Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J Med Chem 2009;52:7446-57
   PubMed Web of Science ®Google Scholar
• Hu L, Lan P, Song Q-L, Synthesis and antibacterial activity of C-12 pyrazolinyl spiro ketolides. Eur J Med Chem 2010;45:5943-9
   PubMed Web of Science ®Google Scholar
• Song Q-L, Guo B-Q, Zhang W, Design, synthesis and antibacterial activity of novel ketolides bearing an aryltetrazolyl-substituted alkyl side chain. J Antibiot 2011;64:571-81
   PubMed Web of Science ®Google Scholar
• Shaw SJ, Ashley GW, Burlingame MA. 7-Quinolyl ketolide antibacterial agents. US7595300; 2009
   Google Scholar
• Alihodzic S, Fajdetic A, Kobrehel G, Synthesis and antibacterial activity of isomeric 15-membered azalides. J Antibiot 2006;59:753-69
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Fajdetic A, Mutak S. Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials. Bioorg Med Chem 2010;18:8566-82
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Mutak S. Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin a ketolides. J Med Chem 2010;53:5868-80
   PubMed Web of Science ®Google Scholar
• Putnam SD, Castanheira M, Moet GJ, CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 2010;66(4):393-401
   PubMed Web of Science ®Google Scholar
• Roblin PM, Kohlhoff SA, Parker C, In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother 2010;54(3):1358-9
   PubMed Web of Science ®Google Scholar
• Xu G, Tang D, Gai Y, An efficient large-scale synthesis of EDP-420, a first-in-class bridged bicyclic macrolide (BBM) antibiotic drug candidate. Organ Process Res Dev 2010;14(3):504-10
   Web of Science ®Google Scholar
• Kouvela EC, Kalpaxis DL, Wilson DN, Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity. Antimicrob Agents Chemother 2009;53:1411-19
   PubMed Web of Science ®Google Scholar
• Song Q-L, Sun P-H, Chen W-M. Exploring 3D-QSAR for ketolide derivatives as antibacterial agents using CoMFA and CoMSIA. Lett Drug Des Discov 2010;7:149-59
   Web of Science ®Google Scholar
• Zou L, Chen Y, You Q, 2D-QSAR and HQSAR study on quantitative structure-activity relationship of 6-O-aryl ketolides derivatives. Zhongguo Yaoke Daxue Xuebao 2010;41:208-15
   Google Scholar
• Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008;8(18):1555-72
   PubMed Web of Science ®Google Scholar
• Dean P, Lloyd D, Todorov N. De novo drug design: integration of structure-based and ligand-based methods. Curr Opin Drug Discov Dev 2004;7(3):347-53
   PubMed Web of Science ®Google Scholar
• Cavasotto CN, Orry W, Andrew J. Ligand docking and structure-based virtual screening in drug discovery. Curr Top Med Chem 2007;7(10):1006-14
   PubMed Web of Science ®Google Scholar
• Roy K, Ojha PK. Advances in quantitative structure activity relationship models of antimalarials. Expert Opin Drug Discov 2010;5(8):751-78
   PubMed Web of Science ®Google Scholar
• Cavasotto CN, Phatak SS. Homology modeling in drug discovery: current trends and applications. Drug Discov Today 2009;14(13):676-83
   PubMed Web of Science ®Google Scholar
• Prado-Prado FJ, Uriarte E, Borges F, Multi-target spectral moments for QSAR and complex networks study of antibacterial drugs. Eur J Med Chem 2009;44(11):4516-21
   PubMed Web of Science ®Google Scholar
• Li X, Ye L, Wang X, Combined 3D-QSAR, molecular docking and molecular dynamics study on thyroid hormone activity of hydroxylated polybrominated diphenyl ethers to thyroid receptors beta. Toxicol Appl Pharmacol 2012;265(3):300-7
   PubMed Web of Science ®Google Scholar
• Prado-Prado FJ, Ubeira FM, Borges F, Unified QSAR & network-based computational chemistry approach to antimicrobials. II. Multiple distance and triadic census analysis of antiparasitic drugs complex networks. J Comput Chem 2010;31(1):164-73
   PubMed Web of Science ®Google Scholar
• Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design-a review. Curr Top Med Chem 2010;10(1):95-115
   PubMed Web of Science ®Google Scholar
• Cramer RD III, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110(18):5959-67
   PubMed Web of Science ®Google Scholar
• Clark M, Cramer RD III, Jones DM, Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases. Tetrahedron Comput Methodol 1990;3(1):47-59
   Google Scholar
• Böhm M, Stürzebecher J, Klebe G. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 1999;42(3):458-77
   PubMed Web of Science ®Google Scholar
• Lan P, Chen WN, Xiao GK, 3D-QSAR and docking studies on pyrazolo 4,3-H qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors. Bioorg Med Chem Lett 2010;20(22):6764-72
   PubMed Web of Science ®Google Scholar
• Lan P, Xie MQ, Yao YM, 3D-QSAR studies and molecular docking on [5-(4-amino-1H-benzoimidazol-2-yl)-furan-2-yl]-phosphonic acid derivatives as fructose-1,6-biphophatase inhibitors. J Comput Aided Mol Des 2010;24(12):993-1008
   PubMed Web of Science ®Google Scholar
• Zeng HH, Zhang HB. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno 1,2-c pyrazoles as VEGFR-2 kinase inhibitors. J Mol Graph 2010;29(1):54-71
   Google Scholar
• Prado-Prado F, García-Mera X, Escobar M, 3D MI-DRAGON: new model for the reconstruction of US FDA drug-target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE. Curr Top Med Chem 2012;12(16):1843-65
   PubMed Web of Science ®Google Scholar
• Riera-Fernández P, Martín-Romalde R, Prado-Prado FJ, From QSAR models of drugs to complex networks: state-of-art review and introduction of new Markov-spectral moments indices. Curr Top Med Chem 2012;12(8):927-60
   PubMed Web of Science ®Google Scholar
• Prado-Prado F, García-Mera X, Escobar M, 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. Eur J Med Chem 2011;46(12):5838-51
   PubMed Web of Science ®Google Scholar
• González-Díaz H, Prado-Prado F, Ubeira FM. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem 2008;8(18):1676-90
   PubMed Web of Science ®Google Scholar
• SYBYL 8.1, Tripos Inc., St. Louis, MO, USA
   Google Scholar
• Wold S, Ruhe A, Wold H, The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comp 1984;5:735-43
   Web of Science ®Google Scholar
• Ojha PK, Mitra I, Das RN, Further exploring rm2 metrics for validation of QSPR models. Chemom Intell Lab Syst 2011;107(1):194-205
   Web of Science ®Google Scholar
• Roy K, Mitra I, Kar S, Comparative Studies on Some Metrics for External Validation of QSPR Models. J Chem Inf Model 2011;52(2):396-408
   Web of Science ®Google Scholar
• Available from: http://203.200.173.43:8080/rmsquare/
   Google Scholar
• Heggelund A, Undheim K. Preparation of cyclic 2′,3′-carbamate derivatives of erythromycin macrolide antibiotics. Bioorg Med Chem 2007;15:3266-77
   PubMed Web of Science ®Google Scholar
• LeTourneau N, Vimal P, Klepacki D, Synthesis and antibacterial activity of desosamine-modified macrolide derivatives. Bioorg Med Chem Lett 2012;22:4575-8
   PubMed Web of Science ®Google Scholar
• Kubinyi H. QSAR and 3D QSAR in drug design Part 1: methodology. Drug Discov Today 1997;2(11):457-67
   Web of Science ®Google Scholar
• Kubinyi H. QSAR and 3D QSAR in drug design Part 2: applications and problems. Drug Discov Today 1997;2(12):538-46
   Web of Science ®Google Scholar
• Chung JY, Chung HW, Cho SJ, QM/MM based 3D QSAR models for potent B-Raf inhibitors. J Comput Aided Mol Des 2010;24(5):385-97
   PubMed Web of Science ®Google Scholar
• Gupta P, Roy N, Garg P. Docking-based 3D-QSAR study of HIV-1 integrase inhibitors. Eur J Med Chem 2009;44(11):4276-87
   PubMed Web of Science ®Google Scholar
• Weber KC, Salum LB, Honório KM, Pharmacophore-based 3D QSAR studies on a series of high affinity 5-HT1A receptor ligands. Eur J Med Chem 2010;45(4):1508-14
   PubMed Web of Science ®Google Scholar
• Tu D, Blaha G, Moore PB, Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell 2005;121(2):257-70
   PubMed Web of Science ®Google Scholar
• Golbraikh A, Tropsha A. Beware of q2!. J Mol Graph Model 2002;20(4):269-76
   PubMed Web of Science ®Google Scholar
• Berisio R, Corti N, Pfister P, 23S rRNA 2058A→G alteration mediates ketolide resistance in combination with deletion in L22. Antimicrob Agents Chemother 2006;50:3816-23
   PubMed Web of Science ®Google Scholar
• Dunkle JA, Xiong L, Mankin AS, Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc Natl Acad Sci USA 2010;107:17152-7; S/1-S/3
   PubMed Web of Science ®Google Scholar
• Velvadapu V, Paul T, Wagh B, Desmethyl macrolides: synthesis and evaluation of 4,8,10-tridesmethyl telithromycin. ACS Med Chem Lett 2011;2(1):68-72
   PubMed Web of Science ®Google Scholar
• Velvadapu V, Glassford I, Lee M, Desmethyl macrolides: synthesis and evaluation of 4,10-didesmethyl telithromycin. ACS Med Chem Lett 2012;3:211-15
   PubMed Web of Science ®Google Scholar
• Mwakwari SC, Guerrant W, Patil V, Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton. J Med Chem 2010;53:6100-11
   PubMed Web of Science ®Google Scholar
• Zhang J, Pan X, Wang C, Pharmacophore modeling, 3D-QSAR Studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors. Chem Biol Drug Des 2012;79(3):353-9
   PubMed Web of Science ®Google Scholar